Stay up to date

Latest News

31st January 2026

Expanded Access Program (EAP) for people with Alexander disease to access zilganersen in the United States

Alexander Disease https://alextlc.org/wp-content/uploads/2026/01/Community-Statement-Ionis-Opens-EAP-in-the-US-for-Zilganersen-12.19.25.pdf Ionis has established an Expanded Access Program (EAP) in the United States for people with Alexander Disease to access zilganersen. An Expanded Access Program is a pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product for treatment outside of clinical […]

21st January 2026

Research Summary: January 2026

Research summary of recent leukodystrophy research and clinical trials, includes article summaries and direct links to websites and articles. To access the summary: Research Summary – January 2026 Please be aware these summaries are produced voluntarily by Biomedical Science students and are their interpretations of the information and findings. This information is reviewed by our […]

31st December 2025

Endogenous Repair in Vanishing White Matter

Vanishing White Matter Disease (VWMD) https://onlinelibrary.wiley.com/doi/10.1002/ana.78083?af=R Vanishing White Matter disease (VWMD) is a rare genetic condition that affects the brain’s white matter and is caused by mutations in the EIF2B genes. Individuals with VWMD present progressive white matter loss but can also experience acute episodes of worsening, often during fever or head trauma. Brain MRI […]

31st December 2025

Effects of atidarsagene autotemcel gene therapy on peripheral nerves in late-infantile metachromatic leukodystrophy

Metachromatic leukodystrophy (MLD) https://academic.oup.com/brain/article-abstract/148/10/3727/8120475?redirectedFrom=fulltext Metachromatic leukodystrophy (MLD) is a rare genetic condition in which the absence of the ARSA enzyme leads to the buildup of harmful substances (sulfatides) in the brain and peripheral nerves. This study investigated whether arsa-cel gene therapy, which corrects the faulty ARSA gene, can slow or improve the peripheral nerve damage […]

31st December 2025

Bridging psychiatry and rare genetic diseases: a scoping review of therapeutic strategies and diagnostic delay paired with healthcare economic burden analysis

Leukodystrophies https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03941-8 Rare genetic diseases are medical conditions caused by changes in a single gene and can affect many parts of the body, including the brain. When these genetic changes disrupt brain function, they may first appear as mental-health symptoms such as anxiety, depression, memory difficulties, or unusual behaviour. Because these symptoms closely resemble common […]

31st December 2025

Parental psychosocial outcomes after a positive newborn screen for a lysosomal storage disorder

Krabbe Disease https://www.sciencedirect.com/science/article/pii/S1096719225002264 Newborn screening (NBS) helps identify rare conditions soon after birth, including a group of genetic diseases called lysosomal storage disorders (LSDs). A positive NBS result does not always mean a child is ill; it can also indicate carrier status, harmless “pseudodeficiency” variants, or uncertain results that may never lead to symptoms. This […]

31st December 2025

Impact of HLD6-associated TUBB4A mutant proteins on cell morphogenesis

Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-025-07537-0 Oligodendrocytes are specialised cells in the brain and spinal cord that create myelin, the protective coating that helps nerve signals travel quickly and reliably. In children with hypomyelinating leukodystrophy type 6 (HLD6), myelin does not form properly, leading to motor difficulties, developmental delays, and […]

31st December 2025

Serum NOTCH3Extracellular Domain in Patients With CADASIL

Cerebral Autosomal Dominant Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CADASIL) https://www.neurology.org/doi/10.1212/NXG.0000000000200321 CADASIL is a rare genetic disease that affects the small blood vessels in the brain and can lead to strokes, migraines and progressive cognitive decline. It is caused by changes in the NOTCH3 gene. The current diagnosis and monitoring of CADASIL rely on brain […]

19th December 2025

Research Summary: December 2025

Research summary of recent leukodystrophy research and clinical trials, includes article summaries and direct links to websites and articles. To access the summary: Research Summary – December 2025 Please be aware these summaries are produced voluntarily by Biomedical Science students and are their interpretations of the information and findings. This information is reviewed by our […]

30th November 2025

Critical functional domains in pediatric onset TUBB4A-related leukodystrophy: a clinical and caregiver’s perspective

POLR3 related leukodystrophy https://www.sciencedirect.com/science/article/abs/pii/S0887899425002875 TUBB4A-related leukodystrophy (TUBB4A-LD) is a rare inherited white matter disorder characterised by progressive developmental and motor dysfunction influenced by genotype and age of onset. This study aimed to better understand how the disease affects families and identify Clinical Outcome Assessments (COAs) to optimise future clinical trial designs. The cohort included 58 […]